Is Wegovy Not Working? Understanding Why Doesn’t Wegovy Work for Some People

Last reviewed: June 21, 2026

Last updated: June 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has helped millions lose weight, but clinical data shows roughly 30% of patients have a suboptimal response or hit a weight-loss plateau after initial success. Understanding why medication effectiveness varies between individuals—and what you can do about it—requires looking at the science of your own biology.

Why Semaglutide Effectiveness Varies Between Patients

GLP-1 receptor agonists like semaglutide work by increasing satiety and reducing hunger signals in the brain. However, the strength of your response depends partly on how sensitive your GLP-1 receptors are and how efficiently your body processes the medication. Some patients have genetic variants that reduce GLP-1 receptor expression or function, meaning their cells respond less strongly to the same dose.

The PlexusDx Precision Peptide Genetic Test reports on variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Dosing escalation matters too. Many patients require doses at the higher end of the therapeutic range to see results, yet some never reach adequate satiety even at maximum doses. This individual variation is not a failure of the medication—it reflects the biological diversity of human weight-loss physiology.

Genetic Factors That Reduce GLP-1 Medication Response

Your DNA contains specific instructions for how many GLP-1 receptors your pancreatic beta cells and brain neurons can produce. The GLP1R gene variant rs6923761 is associated with reduced receptor sensitivity in some individuals; patients carrying certain alleles may experience a blunted appetite-suppression effect even at therapeutic doses. Similarly, the GIPR rs1800437 variant affects glucose-dependent insulinotropic peptide signaling, which works alongside GLP-1 pathways to regulate blood sugar and satiety.

The FTO gene (rs9939609) influences your intrinsic appetite drive and metabolic rate. People with the risk allele tend to have higher baseline hunger hormones and lower energy expenditure, which can make semaglutide less effective as a standalone therapy. The MC4R rs17782313 variant affects melanocortin signaling in the hypothalamus—a master control center for appetite. Individuals with this variant often require additional metabolic support or dual-compound approaches.

PlexusDx maps 14 genetic pathways and 49 peptides relevant to weight regulation and GLP-1 response. Rather than guessing whether semaglutide will work, the Precision Peptide Genetic Test reveals your predispositions across multiple metabolic systems, enabling your provider to choose the right medication and dosing strategy upfront.

What to Do If Semaglutide Plateaus or Fails

If you've hit a weight-loss plateau after 12–16 weeks on a stable semaglutide dose, several evidence-based options exist. First, confirm you're at an adequate dose; many patients benefit from titrating to the maximum tolerated level (2.4 mg weekly for injectable semaglutide). If you're already at maximal dose and response is suboptimal, your next step is to assess whether a different compound class might work better.

Tirzepatide is a dual GLP-1/GIP receptor agonist that activates both the GLP-1 pathway and the glucose-dependent insulinotropic peptide (GIP) pathway simultaneously. Because tirzepatide engages an additional satiety mechanism, patients who don't respond well to semaglutide alone often see improved weight loss with tirzepatide. PlexusDx Compounded Tirzepatide Injection is $289/mo month-to-month (or $249/mo on the 6-month plan), and your dose may need to go up—but your price won't, because PlexusDx pricing is flat per medication regardless of dose level.

For some patients, a combination approach works best. PlexusDx GLP-Squared Injection combines compounded semaglutide and tirzepatide in one formulation, at $289/mo month-to-month, or from $249/mo on the 6-month plan. This dual-compound option targets multiple appetite and metabolic pathways at once, increasing the likelihood of meaningful weight loss in patients who haven't responded adequately to monotherapy.

Personalized Treatment Selection with PlexusDx Genetic Testing

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

PlexusDx serves all 50 states with no insurance required, no membership fees, and HSA/FSA eligibility. Compounded Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan); if genetic testing suggests tirzepatide is a better fit, you can switch without flat per-compound pricing adjustments. Your PlexusDx provider can use your genetic data to set realistic expectations, optimize dosing, and proactively adjust your treatment plan to prevent plateaus.

The science of personalized weight loss is no longer theoretical. By understanding your genetic predispositions, you and your provider can move past ineffective medications faster and reach your weight-loss goals with greater certainty and fewer wasted months on treatments that won't work for your body.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How long should I try semaglutide before deciding it's not working?

Clinical response to semaglutide typically emerges within 4–8 weeks, with maximal weight loss usually achieved by 16–20 weeks on a stable dose. If you're at the maximum tolerated dose (2.4 mg weekly) and haven't seen meaningful weight loss after 12 weeks, or if you've plateaued despite adherence, it's reasonable to consider alternative compounds like tirzepatide.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What's the difference between semaglutide and tirzepatide in terms of weight loss?

Tirzepatide activates both GLP-1 and GIP pathways, while semaglutide activates only GLP-1. In clinical trials, tirzepatide produced numerically greater weight loss than semaglutide at comparable timepoints. For patients who don't respond adequately to semaglutide, switching to tirzepatide often yields better results.

Does PlexusDx genetic testing cost extra, and when can I do it?

The Precision Peptide Genetic Test is $298 performed after your first month of treatment. This timing allows PlexusDx to assess your initial response and integrate genetic insights into ongoing treatment optimization.

Is compounded semaglutide from PlexusDx as effective as brand-name Wegovy?

PlexusDx sources all semaglutide from licensed 503A compounding pharmacies, which operate under strict FDA oversight and quality standards. The active ingredient is bioidentical to brand-name formulations. Effectiveness depends on your individual biology, dose, and adherence—not on whether the medication is brand-name or compounded.

Related Reading

• Why Do Some People Find Certain Foods Bitter While Others Do Not
• Why Do Some People Tolerate Dairy While Others Don T Is It Genetic
• Glp 1 Plateau Not Working Anymore Plexusdx
• Why Are Some People Naturally Organized And Accountable While Others Struggle

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.